Vincent Brichard

Direktor/Vorstandsmitglied bei

eTheRNA immunotherapies NV

Health Technology

Consumer Services

Finance

Profil

Vincent Brichard currently works at ImCyse SA, as Director, eTheRNA immunotherapies NV, as Director, Imcheck Therapeutics SAS, as Director from 2019, FoRx Therapeutics AG, as Director, Nouscom Srl, as Director, Egle Therapeutics SAS, as Director from 2025, and EQT Life Sciences Group BV, as Venture Partner from 2015.
Dr. Brichard also formerly worked at Kiadis Pharma BV, as Member-Supervisory Board, Celyad Oncology SA, as Vice President, and Kiadis Pharma NV, as Independent Member-Supervisory Board.
Dr. Brichard received his doctorate degree from Katholieke Universiteit Leuven, graduate degree from Université Catholique de Louvain, Masters Business Admin degree from Harvard Business School, and doctorate degree from Ludwig Institute For Cancer Research (Belgium).

Aktive Positionen von Vincent Brichard

Unternehmen	Position	Beginn
eTheRNA immunotherapies NV eTheRNA immunotherapies NV BiotechnologyHealth Technology Operates as a technology platform that develops mRNA and lipid nanoparticle therapeutics	Direktor/Vorstandsmitglied	-
LSP Management Group BV LSP Management Group BV Investment ManagersFinance EQT Life Sciences invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, medical devices, diagnostics and healthtech sectors. It provides financing for early and later stage capital requirements with an investment size of EUR 10 – 60 million.	Private Equity Investor	01.01.2015
Imcheck Therapeutics SAS Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research	Direktor/Vorstandsmitglied	04.12.2019
FoRx Therapeutics AG FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops cancer treatment compounds	Direktor/Vorstandsmitglied	-
Egle Therapeutics SAS Egle Therapeutics SAS BiotechnologyHealth Technology Operates as a biotechnology company that designs modulate regulatory T cells to balance immunity for the treatment of cancer and autoimmune diseases	Direktor/Vorstandsmitglied	-
ImCyse SA ImCyse SA BiotechnologyHealth Technology Engages in the development of curative therapies in the field of immune and allergic pathologies	Direktor/Vorstandsmitglied	-
Nouscom Srl Nouscom Srl Miscellaneous Commercial ServicesCommercial Services Operates as a next-generation immunotherapy company that develops engineered viral vectored vaccines for treatment of cancer	Direktor/Vorstandsmitglied	-

Alle aktiven Positionen von Vincent Brichard

Ehemalige bekannte Positionen von Vincent Brichard

Unternehmen	Position	Ende
KIADIS PHARMA N.V.	Direktor/Vorstandsmitglied	-
CELYAD ONCOLOGY SA	Corporate Officer/Principal	-
░░░░░░ ░░░░░░ ░░	░░░░░░░░░░░░░░░░░░░░░░░░░░	-

Sehen Sie sich die Erfahrung von Vincent Brichard im Detail an

Ausbildung von Vincent Brichard

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Vincent Brichard im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	14
LSP Management Group BV LSP Management Group BV Investment ManagersFinance EQT Life Sciences invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, medical devices, diagnostics and healthtech sectors. It provides financing for early and later stage capital requirements with an investment size of EUR 10 – 60 million.	Finance
Katholieke Universiteit Leuven Katholieke Universiteit Leuven Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Kiadis Pharma BV Kiadis Pharma BV Pharmaceuticals: MajorHealth Technology Operates as a is a clinical stage biopharmaceutical company focused on research, development and future commercialization of cell based immunotherapy products	Health Technology
Université Catholique de Louvain Université Catholique de Louvain Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Celyad Oncology SA Celyad Oncology SA BiotechnologyHealth Technology Develops immuno-oncology and cardiology products	Health Technology
ImCyse SA ImCyse SA BiotechnologyHealth Technology Engages in the development of curative therapies in the field of immune and allergic pathologies	Health Technology
Harvard Business School Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Kiadis Pharma NV Kiadis Pharma NV Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company focused on research, development and commercialization of cell based immunotherapy products	Health Technology
Ludwig Institute For Cancer Research (Belgium) Ludwig Institute For Cancer Research (Belgium) Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
eTheRNA immunotherapies NV eTheRNA immunotherapies NV BiotechnologyHealth Technology Operates as a technology platform that develops mRNA and lipid nanoparticle therapeutics	Health Technology
Imcheck Therapeutics SAS Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research	Health Technology
FoRx Therapeutics AG FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops cancer treatment compounds	Health Technology
Nouscom Srl Nouscom Srl Miscellaneous Commercial ServicesCommercial Services Operates as a next-generation immunotherapy company that develops engineered viral vectored vaccines for treatment of cancer	Commercial Services
Egle Therapeutics SAS Egle Therapeutics SAS BiotechnologyHealth Technology Operates as a biotechnology company that designs modulate regulatory T cells to balance immunity for the treatment of cancer and autoimmune diseases	Health Technology